Comparative effectiveness of infliximab and tofacitinib in advanced therapy-naive and -exposed patients with ulcerative colitis: a multicenter real-world study.

What To Know

This is a real-world, retrospective study from multiple centers covering initiations between 2010 and 2025, with the primary analysis restricted to when both drugs were available (from May 2018 onward in Japan).

The study separately analyzed AT-naive and AT-exposed patients using overlap weighting and reports week 14 and week 52 remission, plus 3-year treatment persistence.

The reported 52-week corticosteroid-free remission was higher with tofacitinib in AT-exposed patients (38.8% vs 19.0%; OR 2.71) and numerically favored tofacitinib in AT-naive patients (64.5% vs 43.9%; OR 2.32) though the latter did not reach statistical significance.

Three-year persistence differences were not statistically significant but numerically favored tofacitinib in AT-naive patients. The authors describe the findings as exploratory. If you are comparing these treatments with your clinician, note this study is observational and retrospective; it can suggest associations but not prove causation.

Discussion with your care team should consider individual factors such as prior treatment history, comorbidities, safety profiles, and formulation/access issues.